References

1. Wang B, Meng XJ. Hepatitis E virus: host tropism and zoonotic infection. Curr Opin Microbiol. 2021;59:8-15.
2. Denner J. Hepatitis E virus (HEV)-The Future. Viruses.2019;11(3).
3. Denner J, Pischke S, Steinmann E, Blumel J, Glebe D. Why all blood donations should be tested for hepatitis E virus (HEV). BMC Infect Dis. 2019;19(1):541.
4. Dudareva S, Faber M, Zimmermann R, et al. [Epidemiology of viral hepatitis A to E in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022;65(2):149-158.
5. Adlhoch C, Avellon A, Baylis SA, et al. Hepatitis E virus: Assessment of the epidemiological situation in humans in Europe, 2014/15. J Clin Virol. 2016;82:9-16.
6. Zhao C, Wang Y. Laboratory Diagnosis of HEV Infection. Adv Exp Med Biol. 2016;948:191-209.
7. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol.2018;68(6):1256-1271.
8. Abravanel F, Goutagny N, Joffray R, et al. Performance characteristics of the VIDAS(R) ANTI-HEV IgM and IgG assays. J Clin Virol. 2019;112:10-14.
9. Abravanel F, Parraud D, Chapuy-Regaud S, et al. Diagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay.Viruses. 2022;14(5).
10. Kmush BL, Labrique AB, Dalton HR, et al. Two Generations of ”Gold Standards”: The Impact of a Decade in Hepatitis E Virus Testing Innovation on Population Seroprevalence. Am J Trop Med Hyg.2015;93(4):714-717.
11. Pas SD, Streefkerk RH, Pronk M, et al. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol. 2013;58(4):629-634.
12. Sommerkorn FM, Schauer B, Schreiner T, Fickenscher H, Krumbholz A. Performance of Hepatitis E Virus (HEV)-antibody tests: a comparative analysis based on samples from individuals with direct contact to domestic pigs or wild boar in Germany. Med Microbiol Immunol.2017;206(3):277-286.
13. Agresti A, Coull BA. Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions. The American Statistician. 1998;52(2):119-126.
14. Dichtl K, Zimmermann J, Koeppel MB, Bohm S, Osterman A. Evaluation of a Novel CLIA Monotest Assay for the Detection of Anti-Hepatitis E Virus-IgG and IgM: A Retrospective Comparison with a Line Blot and an ELISA. Pathogens. 2021;10(6).
15. Shrestha AC, Flower RL, Seed CR, Stramer SL, Faddy HM. A Comparative Study of Assay Performance of Commercial Hepatitis E Virus Enzyme-Linked Immunosorbent Assay Kits in Australian Blood Donor Samples. J Blood Transfus. 2016;2016:9647675.
16. Vollmer T, Diekmann J, Eberhardt M, Knabbe C, Dreier J. Monitoring of Anti-Hepatitis E Virus Antibody Seroconversion in Asymptomatically Infected Blood Donors: Systematic Comparison of Nine Commercial Anti-HEV IgM and IgG Assays. Viruses. 2016;8(8).
17. Wenzel JJ, Preiss J, Schemmerer M, Huber B, Jilg W. Test performance characteristics of Anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates. J Infect Dis. 2013;207(3):497-500.
18. Ferguson M, Walker D, Mast E, Fields H. Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus. Biologicals. 2002;30(1):43-48.
19. Fogeda M, de Ory F, Avellon A, Echevarria JM. Differential diagnosis of hepatitis E virus, cytomegalovirus and Epstein-Barr virus infection in patients with suspected hepatitis E. J Clin Virol.2009;45(3):259-261.